17α-Ethinyl-androst-5-ene-3β, 17β-diol, a novel potent oral radioprotective agent, confers radioprotection of hematopoietic stem and progenitor cells in a granulocyte colony stimulating factor-independent manner

To develop a novel oral radioprotector, the radioprotective effects of 17α-Ethinyl-androst-5-ene-3β,17β-diol (EAD) were evaluated in mice subjected to total-body irradiated mice. Oral administration of EAD before irradiation significantly improved survival after lethal irradiation and promoted multilineage reconstitution by stimulating hematopoietic stem and progenitor cells in a G-CSF independent manner. Given its oral efficacy and low toxicity, EAD has potential as an optimal radioprotector for use by first responders as well as at-risk civilian populations.

https://ift.tt/2OZJVcd